Sputnik spoke to Peter Doshi, British Medical Journal's (BMJ) Associate Editor, about this story.
Sputnik: So Peter, this is quite a significant and shocking discovery. Could you tell our listeners a little bit more about this investigation and the findings of these reports?
Peter Doshi: This story that I’ve written focussing on the Pandemrix vaccine which was widely used across the world; it was used by tens of millions of people in 2009 and 2010. This is a vaccine that doesn’t anymore; it’s been taken off the market, but was something that was widely used that therefore was important. In late 2010, there were many cases of narcolepsy appearing that really brought the drug into the public spotlight and lawsuits ensued and these are is still in the courts. My investigation focusses on a document a lawsuit that was compiled by GSK, it’s a safety report, and what’s most concerning about this report is that they suggest multiple possible safety problems and what very interesting is that it’s not just that there’s a possible safety problem there, but the timing of the reports. They are dated. The earliest report I have dates back to December 2009, which is a time when people still hadn’t gotten the vaccine and so had this information, which hasn’t been public until now, come out; people may have made different decision than they actually did. They may have made a different decisions.
Peter Doshi: We can’t draw Cause and Effect conclusions. You mentioned what does this say about the speed of getting vaccines to market… that’s a complex topic because on the one hand you have a concern about shortcuts happening that will compromise patient safety, but on the other hand if you are facing a very severe illness where you need to get some kind of intervention on the market quickly, there will be a huge demand for that and that’s reasonable. What this points to is in the part, the complexities of getting something to market quickly but I think the more important lesson is what are we doing once we put these drugs on the market? What kind of information are we collecting and how transparent in terms of dissemination of the information we are collecting in real time. The less information you have at the time of approval the more important it is to get more information after approval so you can alter or adjust decision making depending on what you’re learning.
Peter Doshi: I find the lack of response to these things unacceptable personally. I feel that there is an absolute need to address these questions. There is an absolute need that we learn from these lessons and by not sharing the story we cannot really understand what’s going on here. It doesn’t increase confidence in the system.
The views expressed in this article are those of the speaker, and do not necessarily reflect those of Sputnik.
